Drugs / Eperisone
Eperisone
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01869985 | Aug → Sep 2013 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03424707 | Mar → Aug 2016 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01806818 | Feb → Jul 2013 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02040415 | Mar → Jul 2014 | — | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00327730 | Apr → Jun 2006 | — | Eisai Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02289274 Comparator | Nov → Dec 2019 | — | NVP Healthcare | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01300312 Comparator | Feb → Jun 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03337607 Comparator | Nov 2017 → Apr 2019 | — | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eperisone | “Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients” NCT01806818 ↗7“Eperisone Hydrochloride 50mg Tablet” NCT01869985 ↗ |
| Known as | DW-1030 | “DW-1030(eperisone HCl) 75mg” NCT02040415 ↗ |
| Known as | Eperisona | ChEMBL registry synonym — accepted as the source's own label CHEMBL1902981 ↗ |
| Known as | eperisone HCl | “DW-1030(eperisone HCl) 75mg” NCT02040415 ↗ |
| Known as | Myonal | “Patients will be treated with either Eperisone-HCl (Myonal) or placebo for a period of 14 days.” NCT00327730 ↗ |
| Known as | Myonal Tab. | “Myonal Tab.(eperisone HCl) 50mg” NCT02040415 ↗ |
| Modality | Small molecule | — CHEMBL1902981 ↗ |
| Route | Oral | “eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals” NCT01300312 ↗ |